Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial

INTRODUCTION: In the IMPACT trial, single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced moderate/severe exacerbation rates versus FF/VI or UMEC/VI dual therapy in patients with chronic obstructive pulmonary disease (COPD); however, pneumonia incidence was hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpin, David M. G., Criner, Gerard J., Dransfield, Mark T., Han, MeiLan K., Hartley, Benjamin, Harvey, Catherine, Jones, C. Elaine, Kato, Motokazu, Lange, Peter, Lettis, Sally, Lomas, David A., Martinez, Fernando J., Martin, Neil, Singh, Dave, Wise, Robert, Zheng, Jinping, Lipson, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137798/
https://www.ncbi.nlm.nih.gov/pubmed/33201438
http://dx.doi.org/10.1007/s41030-020-00136-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137798/
https://www.ncbi.nlm.nih.gov/pubmed/33201438
http://dx.doi.org/10.1007/s41030-020-00136-3

Ejemplares similares